METAP2 inhibitors and methods of treating obesity
US10588904B2 · kind B2 · utility
2Cited by
38References
47Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 30, 2018 |
| Grant date | Mar 17, 2020 |
| Priority date | — |
| Expiry date | May 30, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P5/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.